Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DTX401 in Glycogen Storage Disease Type Ia
NCT05139316Phase 3Completed
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Nov 2021
- Primary completion
- Feb 2024
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 9
01
Overview
A Phase 3 trial of pariglasgene brecaparvovec in Glycogen storage disease type Ia (GSDIa), sponsored by Ultragenyx Pharmaceutical Inc.. Started Nov 2021; status: completed.
02
Drugs
pariglasgene brecaparvovec
03
Conditions
Glycogen storage disease type Ia (GSDIa)
Beyond the preview
Go deeper on NCT05139316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05139316.